



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s)	Riccardo FERRACINI		
Address(es)	Via Valdocco 1-10133 Torino		
Telephone(s)	(+39) 011 6684208	Mobile:	(+39) 335 7055868
E-mail	ferracini@edu.unige.it		
Nationality	Italian		
Date of birth	April 28 th 1958		
Gender	male		

Occupational field

- Staff Orthopaedics Surgeon, Department of "Scienze Chirurgiche e Diagnostiche Integrate" (DISC), University of Genoa and IRCCS San Martino Hospital, Genoa
- Associate Professor in Orthopaedics, Department of "Scienze Chirurgiche e Diagnostiche Integrate" (DISC), University of Genoa and IRCCS San Martino Hospital, Genoa
- Consultant Research Fellow, Department of "Scienze Chirurgiche e Diagnostiche Integrate" (DISC), University of Genoa and IRCCS San Martino Hospital, Genoa

Clinical Work experience

Dates	September 2017-present
Position Held	Associate Professor in Orthopaedics, Department of "Scienze Chirurgiche e Diagnostiche Integrate" (DISC)
Name of the employer	University of Genoa and IRCCS San Martino Hospital, Genoa
Dates	2014-2017
Position Held	Senior Orthopaedics Surgeon
Name of the employer	Orthopaedic Trauma Center (C.T.O.), Turin
Dates	2002-2014
Position Held	Staff Orthopedics Surgeon
Name of the employer	Department of Orthopaedics Surgery, A.O.U. Citta' della Salute e della Scienza, Turin
Dates	1998-2002
Position Held	Staff Orthopaedics Surgeon
Name of the employer	"Ospedale Mauriziano", Turin

Dates	1997-1998
Position Held	Staff Orthopaedics Surgeon
Name of the employer	Orthopedic Surgery Institute "Regina Maria Adelaide", Turin
Dates	1996-1997
Position Held	Fellow
Name of the employer	Orthopaedics Surgery at the Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Canada
Dates	1992-1996
Position Held	Staff Orthopaedics Surgeon
Name of the employer	Savigliano General Hospital, Savigliano, Cuneo
Dates	1993-1997
Position Held	Resident training
Name of the employer	Orthopaedics Surgery at Department of Orthopaedics, University of Turin

Research Work Experience

Dates	2002-present
Position Held	Senior Scientist
Name of the employer	Laboratory of Osteoncology at the Center for Experimental Research and Medical Studies (CERMS), A.O.U. Citta' della Salute e della Scienza, Turin
Dates	1999-2001
Position Held	Staff laboratory
Name of the employer	Cancer Genetics Laboratory, IRCC Candiolo, Turin
Dates	1992-2002
Position Held	Consultant Research Associate
Name of the employer	Department of Biomedical Sciences and Oncology, Turin
Dates	1987-1989
Position Held	Research Fellow
Name of the employer	State University of New York, Stony Brook, USA

Teaching Experience

Dates	2017-present
Position Held	Instructional Teacher
Name of the employer	Medical School of Orthopaedics, University of Genoa
Dates	2014-2017
Position Held	Instructional teacher
Name of the employer	Medical School of Orthopaedics, University of Turin
Dates	1993-1998
Position Held	Instructional teacher
Name of the employer	Medical School of Orthopaedics, University of Turin

Education and training

Dates	2018
Title of qualification awarded	National Academic Qualification for Full Professor "Fascia I" domain 06/F4 ("Malattie Apparato Locomotore e Medicina Fisica e Riabilitativa"), "SSD MED/33 Malattie Apparato Locomotore per il periodo 09/04/2018-09/04/2024"

Dates	2014
Title of qualification awarded	National Academic Qualification for Associate Professor "Fascia II" domain 06/F4 ("Malattie Apparato Locomotore e Medicina Fisica e Riabilitativa"), "SSD MED/33 Malattie Apparato Locomotore 2013 per il periodo 08/01/2014-08/01/2018"
Dates	1997
Title of qualification awarded	Certified Practice at the College of Physicians and Surgeons of Ontario, Canada
Dates	1989-1992
Title of qualification awarded	P.h.D. Department of Biomedical Science and Oncology-University of La Sapienza, Rome Field of Study: Oncogenes and growth factors in bone tumors
Dates	1984-1989
Title of qualification awarded	Residency in Orthopaedics Orthopaedics Clinic, University of Turin Field of Study: Orthopaedics Oncology

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s)

Self-assessment

European level (*)

English

French

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
	C2		C2		C2		C2		C2
	C2		C2		C2		C2		C2

(*) [Common European Framework of Reference for Languages](http://europass.cedefop.europa.eu)

Additional Information (I)

AWARDS and FELLOWSHIPS

2016 Research Award from the Bank of Italy for Orthopedics Oncology Research

1987-1989 Fellowship on Cancer Research appointed to State University of New York, Stony Brook, USA

Additional Information (II)**GRANTS**

- 2016 "Compagnia di San Paolo" Foundation, Turin
Study of mesenchymal precursors from adipose tissue in orthopedic and reconstructive oncological surgery.
- 2014 "Cassa di Risparmio di Torino (CRT)" Foundation, Turin
Study of mesenchymal stem cells from adipose tissue for the repair of cartilaginous defects
- 2008-2009 "Regione Piemonte: Ricerca Finalizzata 2008", Italy
Biological mechanisms of prostate carcinoma metastasis: new diagnostic markers.
- 2004-2006 "Ministero della Salute: Ricerca Scientifica Applicata", Italy
Spontaneous osteoclastogenesis: a predictor of the formation of bone metastases from lung cancer.
- 2003-2010 Startup Grant "Compagnia di San Paolo" Foundation, Turin.
- 1994-2002 A.I.R.C. Research grant, Italy.
Study and molecular characterization of osteoblastic tumors.

Additional information (III)**SCIENTIFIC COLLABORATIONS**

- C. Castagnoli, Tissue and Cell Factory Skin Bank, Orthopaedic Trauma Center (C.T.O.), Turin
- A. Bistolfi, Department of Orthopaedics, Orthopaedic Trauma Center (C.T.O.), Turin
- G.C. Isaia e P. D'Amelio, Department of Geriatrics, University of Turin
- P.M. Comoglio e M.F. Di Renzo, Cancer Genetics Center, IRCC Candiolo, Turin
- P. Ruggieri, Department of Orthopaedics and Oncology, University of Padua
- N. Baldini e K. Scotlandi, Oncology laboratories, Istituti Ortopedici Rizzoli, Bologna.
- M. Grano, Institute of Histology, University of Bari.
- G. Sozzi e G. Bertolini, Molecular Genomics, "Istituto Tumori" Milan
- J.H. Healey, Musculoskeletal Oncology, Sloan-Kettering Cancer Center, New York, Stati Uniti d'America.
- J. Wunder, University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Canada.
- E. Masterson, Oncology Division, Department Orthopaedics, St. Nesses's Hospital Croom County, Irlanda.
- V. Preat, Louvain Drug Research Institute, Université Catholique de Louvain, Belgio.

Additional Information (IV)

SELECTED PUBLICATIONS (last 15 years)

Roato I, Belisario DC, Compagno M, Lena A, Bistolfi A, Maccari L, Mussano F, Genova T, Godio L, Perale G, Formica M, Cambieri I, Castagnoli C, Robba T, Felli L, **Ferracini R**. Concentrated adipose tissue infusion for the treatment of knee osteoarthritis: clinical and histological observations. *Int Orthop*. 2018 Oct 11. [Epub ahead of print]. IF 2015: 2.53

Ferracini R, Martínez Herreros I, Russo A, Casalini T, Rossi F, Perale G. Scaffolds as Structural Tools for Bone-Targeted Drug Delivery. *Pharmaceutics*. 2018 Aug 8;10(3). Review. IF 2018: 3.746

Mussano F, Genova T, Petrillo S, Roato I, **Ferracini R**, Munaron L. Osteogenic Differentiation Modulates the Cytokine, Chemokine, and Growth Factor Profile of ASCs and SHED. *Int J Mol Sci*. 2018 May 14;19(5). IF 2017: 3.687

Roato I, Belisario DM, Compagno M, Verderio L, Sighinolfi A, Mussano F, Genova T, Veneziano F, Pertici G, Perale G and **Ferracini R**. Adipose-derived stromal vascular fraction/xenohybrid bone scaffold: an alternative source for bone regeneration. *Stem Cells Int*. 2018 (29);2018:4126379. IF 2016: 3.54

Roato I and **Ferracini R**. Cancer stem cells, bone and tumor microenvironment: key players in bone metastases. *Cancers (Basel)*. 2018 Feb 20;10(2). IF 2018:5.326

Bistolfi A, Zanovello J, **Ferracini R**, Allisiardi F, Lioce E, Magistrini E, Berchiolla P, Da Rold Massazza G. Evaluation of the Effectiveness of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty: A Meta-Analysis. *Am J Phys Med Rehabil*. 2018 Feb;97(2):123-130. IF 2016: 1.734

Roato I, Alotto D, Belisario DC, Casarin S, Fumagalli M, Cambieri I, Piana R, Stella M, **Ferracini R**, Castagnoli C. Adipose Derived-Mesenchymal Stem Cells Viability and Differentiating Features for Orthopaedic Reparative Applications: Banking of Adipose Tissue. *Stem Cells Int*. 2016; 2016:4968724. IF 2016: 3.54

D'Amico L, Belisario D, Migliardi G, Grange C, Bussolati B, D'Amelio P, Perera T, Dalmasso E, Dalle Carbonare L, Godio L, Comoglio P, Trusolino L, **Ferracini R**, Roato I. C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. *Oncotarget*. 2016 Jul 19;7(29):45525-45537. IF 2016: 5.168

Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, **Ferracini R**, Saraci E, Omedé P, Riganti C, Palumbo A, Boccadoro M, Massaia M. Anergic bone marrow V α 9V β 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. *Oncoimmunology*. 2015 May 26;4(11). IF 2016: 7.719

Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, Tortoreto M, Milione M, **Ferracini R**, Mariani L, Pastorino U, Roato I*, Sozzi G, Roz L. Microenvironment modulated metastatic CD133+/CXCR4+/EpCAM- lung cancer initiating cells sustain tumor dissemination and correlate with poor prognosis. *Cancer Res*. 2015 Jul 3. IF 2016: 9.122

Foglietta M, Castella B, Mariani S, Coscia M, Godio L, **Ferracini R**, Ruggeri M, Muccio V, Omedé P, Palumbo A, Boccadoro M, Massaia M. The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. *Haematologica*. 2014 Oct;99(10):1605-10. IF 2016: 7.702

D'Amelio P, Roato I, Oderda M, Soria F, Zitella A, **Ferracini R**, Mengozzi G, Gontero P, Isaia GC. DKK-1 in prostate cancer diagnosis and follow up. *BMC Clin Pathol*. 2014 Mar 21;14(1):11. IF not available

Chillemi A, Zaccarello G, Quarona V, Lazzaretti M, Martella E, Giuliani N, **Ferracini R**, Pistoia V, Horenstein AL, Malavasi F. CD38 and bone marrow microenvironment. *Front Biosci (Landmark Ed)*. 2014 Jan 1;19:152-62. Review. IF 2016: 3.736

Roato I and **Ferracini R**. Solid tumours show osteotropism: mechanisms of bone metastases. *Clinic Rev Bone Miner Metab*. 2013, 11: 87-93. IF not available

Leite SC, Corrêa DG, Doring TM, Kubo TT, Netto TM, Ferracini R, Ventura N, Bahia PR, Gasparetto EL. Diffusion tensor MRI evaluation of the corona radiata, cingulate gyri, and corpus callosum in HIV patients. *J Magn Reson Imaging*. 2013 Dec;38(6):1488-93. IF 2016: 3.083

D'Amico L., Ruffini E., **Ferracini R.**, Roato I. Low dose of IL-12 stimulates T cell response in cultures of PBMCs derived from Non Small Cell Lung Cancer patients. *Journal of Cancer Therapy* 2012, 3, 337-342. IF not available

Dani N, Olivero M, Mareschi K, van Duist MM, Miretti S, Cuvertino S, Patané S, Calogero R, **Ferracini R**, Scotlandi K, Fagioli F, Di Renzo MF. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. *J Bone Miner Res*. 2012 Jun;27(6):1322-34. IF 2016: 6.284

D'Amelio P, Roato I, D'Amico L, Veneziano L, Suman E, Sassi F, Bisignano G, **Ferracini R**, Gargiulo G, Castoldi F, Pescarmona GP, Isaia GC. Bone and bone-marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. *Osteoporosis International*, 22 (11), 2011, pp2869-2877. IF 2016: 3.591.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Gai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Streponi I, Roato I, **Ferracini R**, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaia H, Bernareggi A, Inghirami G. CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib. *Blood*. 2008, Mar 1;111(5):2765-75. IF 2016: 13.164.

D'Amelio P, Cristofaro MA, D'Amico L, Veneziano L, Roato I, Sassi F, Bisignano G, Saracco M, Pellerito R, Patane S, **Ferracini R**, Pescarmona GP, Isaia GC. Iloprost modulates the immune response in systemic sclerosis. *BMC Immunol*. 2010 Dec 15;11(1):62. IF 2016: 2.485

Roato I, Porta F, Mussa A, D'Amico L, Fiore L, Garelli D, Spada M, **Ferracini R**. Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase. *PlosOne*, 2010 Nov 30. IF 2016: 2.806

Roato I, Caldo D, D'Amico L, D'Amelio P, Godio L, Patané S, Astore F, Grappiolo G, Boggio M, Scagnelli R, Molfetta L, **Ferracini R**. Osteoclastogenesis in peripheral blood mononuclear cell cultures of periprosthetic osteolysis patients and the phenotype of T cells localized in periprosthetic tissues. *Biomaterials*. 2010 Oct;31(29):7519-25. IF 2016: 8.402

Lolli ML, Rolando B, Tosco P, Chaurasia S, Di Stilo A, Lazzarato L, Gorassini E, **Ferracini R**, Oliaro-Bosso S, Fruttero R, Gasco A. Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-Bps). *Bioorganic & Medicinal Chemistry*. 2010 Apr;18(7): 2428-2438. IF 2016: 2.93

Roato I, Caldo D, Godio L, D'Amico L, Giannoni P, Morello E, Quarto R, Molfetta L, Buracco P, Mussa A, **Ferracini R**. Bone invading NSCLC cells produce IL-7: mice model and human histologic data. *BMC Cancer*. 2010 Jan 12;10:12. IF 2016: 3.288

Porta F, Roato I, Mussa A, Repici M, Gorassini E, Spada M, **Ferracini R**. Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria. *J Inherit Metab Dis*. 2008 Oct 17. IF 2016: 3.97

Roato I, Gorassini E, Buffoni L, Lyberis P, Ruffini E, Bonello L, Baldi I, Ciuffreda L, Mussa A and **Ferracini R**. Spontaneous osteoclastogenesis as a predictive factor for bone metastases from Non-Small Cell Lung Cancer. *Lung Cancer*, 2008 Jul; 61(1):109-16. IF 2016: 4.294

Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, **Ferracini R**. Osteoclasts are active in bone forming metastases of prostate cancer patients. *PLoS One*. 2008 3(11):e3627. IF 2016: 2.806.

Miretti S, Roato I, Taulli R, Ponzetto C, Cilli M, Olivero M, Di Renzo MF, Godio L, Albini A, Buracco P, and **Ferracini R**. A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. *PlosOne* 2008 Mar 19; 3(3) e1828. IF 2016: 2.806..

- Roato I, Gorassini E, Brunetti G, Grano M, Ciuffreda L, Mussa A, **Ferracini R**. IL-7 modulates osteoclastogenesis in patients affected by solid tumors. *Ann N Y Acad Sci*. Jun 2007, 1117:377-84. IF 2016: 4.706
- Roato I, Brunetti G, Gorassini E, Grano M, Colucci S, Bonello L, Buffoni L, Ruffini E, Manfredi R, Ottaviani D, Ciuffreda L, Mussa A, **Ferracini R**. (2006). IL-7 up-regulates TNF- α -dependent osteoclastogenesis in patients affected by solid tumor. *PLoS ONE* 1(1): e124. IF 2016: 2.806.
- Patanè S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, **Ferracini R**, Corso S, Giordano S, Comoglio PM, and Di Renzo MF. Met overexpression turns human primary osteoblasts into osteosarcomas. *Cancer Res*. 2006 May 1;66(9), pp.4750-4757. IF 2016: 9.122
- Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, **Ferracini R**. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. *FASEB J*. 2004 Mar;19(2), pp228-230. IF 2016: 5.498
- Cagliero E, **Ferracini R**, Morello E, Scotlandi K, Manara MC, Buracco P, Comandone A, Baroetto Parisi R and N. Baldini. Reversal of multidrug-resistance using valspodar® (psc 833) and doxorubicin in osteosarcoma. *Oncology Reports*. 2004, 12. IF 2016: 2.662
- Coltella N, Manara MC, Cerisano V, Trusolino L, Di Renzo MF, Scotlandi K, **Ferracini R**. Role of the met/hgf receptor in proliferation and invasive behavior of osteosarcoma. *FASEB J*. 2003, 17(9), pp1162-1164. IF 2016: 5.498
- Morello E, Buracco P, Martano M, Peirone B, Capurro C, Valazza A, Cotto D, **Ferracini R**, Sora M. Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. *J Small Anim Pract*. 2001 Feb;42(2):61-6. IF 2016: 1.000

Genoa, July 3rd 2018

Riccardo Ferracini

